Clinical Trials Browser

Phase 2 × Completed × Gefitinib × Clear all

NCT00198380 2024-03-08

Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

Phase 2 Completed

Adenocarcinoma, Bronchiolo-Alveolar

NCT01185158 2023-11-29

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Phase 2 Completed

Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms, Laryngeal Diseases

NCT01833572 2023-07-12

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01185171 2023-05-11

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

Phase 2 Completed

70 enrolled 11 charts

Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms, Laryngeal Diseases

NCT02447419 2022-06-15

Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors

Phase 2 Completed

Other solid neoplasm

Solid Tumor

NCT03170180 2022-06-15

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT02804776 2021-06-02

PROGRESS

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01610336 2021-04-08

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Phase 2 Completed

161 enrolled 32 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01556191 2021-01-08

LADIE

Phase 2 Completed

Lung Neoplasms

NCT01466660 2020-04-07

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Phase 2 Completed

319 enrolled 19 charts

Lung Neoplasms

NCT00025116 2020-04-06

ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2 Completed

Prostatic Neoplasms

NCT01933347 2020-02-06

Third-line Treatment of Gefitinib in NSCLC Patients

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02976116 2019-11-15

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Completed

NSCLC

NCT00014183 2019-11-07

ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer

Phase 2 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01469000 2019-09-10

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

195 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT00126555 2019-08-30

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

Phase 2 Completed

23 enrolled 12 charts

Skin Neoplasms

NCT02179671 2019-08-02

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Phase 2 Completed

32 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00027690 2019-07-23

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Phase 2 Completed

Recurrent Uterine Corpus Carcinoma

NCT02142036 2019-03-13

MetAction

Phase 2 Completed

Neoplasm Metastasis

NCT00025675 2018-06-26

Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT01864681 2018-06-20

CGMT

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00215202 2018-05-17

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Phase 2 Completed

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms

NCT00509002 2017-11-24

Iressa Study in Patients With Salivary Gland Cancer

Phase 2 Completed

37 enrolled 4 charts

Salivary Gland Neoplasms

NCT00452244 2017-08-25

Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Lung Neoplasms

NCT00095836 2017-05-31

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Phase 2 Completed

27 enrolled 16 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT00188617 2017-03-14

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

Phase 2 Completed

Lung Neoplasms

NCT00231465 2017-03-03

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

Phase 2 Completed

44 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

NCT00062062 2016-12-14

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00100945 2016-12-13

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

Phase 2 Completed

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT00059722 2016-08-24

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00519077 2016-07-01

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

44 enrolled 7 charts

Carcinoma, Head and Neck Neoplasms, Neoplasms

NCT01530334 2016-02-23

ICARUS

Phase 2 Completed

61 enrolled 11 charts

Lung Neoplasms

NCT01783834 2016-02-11

Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

Phase 2 Completed

Previous Treated Metastatic Non-small Cell Lung Cancer

NCT00588445 2016-01-22

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Phase 2 Completed

65 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00177242 2016-01-18

Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma

Phase 2 Completed

Neoplasms

NCT00268346 2016-01-05

Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer

Phase 2 Completed

58 enrolled 6 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT00229697 2015-10-05

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

Phase 2 Completed

Breast Neoplasms

NCT00258323 2015-09-30

Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer

Phase 2 Completed

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT00054691 2015-03-13

ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

Phase 2 Completed

40 enrolled 6 charts

Skin Neoplasms

NCT01498562 2014-12-02

DATE

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00077025 2014-07-16

Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00057941 2014-05-12

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

Phase 2 Completed

148 enrolled 7 charts

Breast Neoplasms

NCT00130702 2014-05-01

Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01017679 2013-12-10

Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00066378 2013-10-24

Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00015964 2013-09-05

ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00014170 2013-07-16

Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2 Completed

Glioblastoma, Gliosarcoma

NCT00012337 2013-06-24

ZD 1839 in Treating Patients With Metastatic Kidney Cancer

Phase 2 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00023699 2013-06-24

Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00025350 2013-06-24

Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms